Acute promyelocytic leukemia (APL) is characterized by peculiar biological features and high sensitivity to therapeutic agents such as anthracyclines, all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Because cure rates of up to 80 - 90% have been reported using various combinations of the above agents, future strategies will probably aim at reducing therapy-related toxicity while maintaining therapeutic efficacy. Gemtuzumab ozogamicin (GO) is a calicheamicin-conjugated mAb directed against CD33, a surface antigen highly expressed on APL blasts. GO has been shown to be effective in this disease and better tolerated than conventional chemotherapy.
Breccia, M., & Lo Coco, F. (2011). Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: Mechanisms of action and resistance, safety and efficacy. EXPERT OPINION ON BIOLOGICAL THERAPY, 11(2), 225-234 [10.1517/14712598.2011.543895].
Tipologia: | Articolo su rivista | |
Citazione: | Breccia, M., & Lo Coco, F. (2011). Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: Mechanisms of action and resistance, safety and efficacy. EXPERT OPINION ON BIOLOGICAL THERAPY, 11(2), 225-234 [10.1517/14712598.2011.543895]. | |
Lingua: | English | |
Settore Scientifico Disciplinare: | Settore MED/15 - Malattie del Sangue | |
Revisione (peer review): | Esperti anonimi | |
Tipo: | Articolo | |
Rilevanza: | Rilevanza internazionale | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1517/14712598.2011.543895 | |
Stato di pubblicazione: | Pubblicato | |
Data di pubblicazione: | 2011 | |
Titolo: | Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: Mechanisms of action and resistance, safety and efficacy | |
Autori: | ||
Autori: | Breccia, M; Lo Coco, F | |
Appare nelle tipologie: | 01 - Articolo su rivista |